Identification and verification of key molecules in the epileptogenic process of focal cortical dysplasia

Lingman Wang1, Jianxiong Gui1, Ran Ding1

  • 1Department of Neurology, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatrics, Children's Hospital of Chongqing Medical University, Chongqing, 400014, China.

Metabolic Brain Disease
|November 29, 2024
PubMed

Insights

Focal cortical dysplasia (FCD) linked to drug-resistant epilepsy involves neuroinflammation. Key genes like CYBB and ITGAM may serve as biomarkers for this developmental brain malformation.

Area of Science:

  • Neuroscience
  • Genetics
  • Immunology

Background:

  • Focal cortical dysplasia (FCD) is a frequent pediatric brain malformation.
  • Drug-resistant epilepsy (DRE) often accompanies FCD, but its molecular basis remains elusive.

Purpose of the Study:

  • To elucidate the molecular mechanisms underlying FCD and its association with DRE.
  • To identify potential diagnostic and therapeutic biomarkers for FCD.

Main Methods:

  • Bioinformatic analysis of FCD microarray data from the Gene Expression Omnibus (GEO) database.
  • Differential gene expression (DEG) analysis, WGCNA, and protein-protein interaction (PPI) analysis.
  • Validation of hub genes in a rat model of FCD.

Main Results:

  • Identified 320 DEGs enriched in neuroinflammatory and immune response pathways.
  • Pinpointed five hub genes: CYBB, ITGAM, FCG3A, LY86, and CD86.
  • Validated four hub genes (CYBB, ITGAM, FCG3A, CD86) in vivo, linking them to microglia-mediated neuroinflammation.

Conclusions:

  • Microglia-induced neuroinflammation is closely related to the pathogenesis of epileptic seizures in FCD.
  • The identified hub genes (ITGAM, FCG3A, CD86, CYBB, LY86) show promise as candidate biomarkers for FCD.